Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane...

by Thomas Decker, Ulrike Söling, Antje Hahn, Christoph Maintz, Christian Martin Kurbacher, Ursula Vehling-Kaiser, Dagmar Sent, Peter Klare, Volker Hagen, Marco Chiabudini, Julia Falkenstein, Martin Indorf, Eva Runkel, Karin Potthoff
Published 2020-04-01